Antibody therapy against antibiotic-resistant diarrheagenic Escherichia coli: a systematic review.
Immunotherapy
; 13(15): 1305-1320, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-34463122
ABSTRACT
Over four billion episodes of diarrhea occur annually in developing countries with diarrheagenic Escherichia coli (DEC) outbreaks also being reported, until now bacterial diarrhea is conventionally addressed by the antibiotic treatment regimes. In recent decades, the emergence of antimicrobial-resistant strains has become a major obstacle in diarrheal treatment; hence, novel and ideal therapeutics are needed. Notably, 80% of DEC is resistant to first-class antibiotics. Among the existing strategies, passive immunization is considered as an alternative to combat drug-resistant bacteria. Antibodies specific to an antigen can be used for prophylactic and therapeutic purposes. In this review, we have systematically discussed the effect of passive immunotherapy to combat DEC and explored the types and advancements in antibodies used against antibiotic-resistant DEC.
Key words
Full text:
1
Collection:
01-internacional
Health context:
2_ODS3
/
3_ND
Database:
MEDLINE
Main subject:
Drug Resistance, Bacterial
/
Diarrhea
/
Escherichia coli
/
Immunotherapy
Type of study:
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Immunotherapy
Year:
2021
Document type:
Article